Medical Cannabis in the UK: Europe’s Next Growth Market?

A Market Driven Largely by Private Care

Access through the NHS remains limited and difficult for many patients. As a result, private clinics have become the main driver of patient access. According to recent market data, the UK medical cannabis market is now almost entirely private: more than 99 percent of prescriptions are issued outside the NHS, primarily through private clinics and specialist care providers. One analysis estimates that more than 40 private clinics should be active in the market, including around 20 to 25 specialist medical cannabis providers with regular prescribing activity. By the end of 2025, around 80,000 patients are expected to have received treatment through the private system (groweriq 02.05.2026).

Imports are rising sharply as well: in 2025, around 30 tonnes of medical cannabis flower were imported into the UK, more than twice as much as in the previous year (BoC 20.05.2026). This makes the UK one of Europe’s most dynamic medical cannabis markets, even though access still depends heavily on private care.

Private Care in Response to Limited Access

This development shows that patient demand is real. Patients are looking for additional treatment options, doctors are gaining experience, and private providers are building care pathways where the public system remains constrained by high barriers and limited resources. Germany is facing a related debate: the reimbursement of medical cannabis flower by statutory health insurance is currently under discussion as part of the GKV Contribution Rate Stabilisation Act. Against the backdrop of a financially strained NHS, private healthcare has become an important route into medical cannabis treatment in the UK. It can improve access, support patient education, and help medical cannabis become more widely recognised as a legitimate treatment option.

Germany as a European Reference Market

This is where there is a clear opportunity for Europe. Markets such as the UK can draw on the experience of countries that have already integrated medical cannabis more deeply into regular care. In Germany, medical cannabis has been prescribable and reimbursable by statutory health insurance since 2017. Since April 2024, medical cannabis has no longer been classified as a narcotic. Instead, it is regulated under the Medical Cannabis Act, which has significantly reduced bureaucracy for prescribing and dispensing.

This regulatory shift has had a noticeable impact on the German market. Prescriptions, imports, and market volumes have all increased significantly. Market analyses now identify Germany as Europe’s largest medical cannabis market and an important hub for imports and distribution. With its pharmaceutical infrastructure, pharmacy expertise, regulatory experience, and established quality processes, Germany is becoming a central reference point for medical cannabis in Europe.

An Opportunity for European Cooperation

The UK market is no longer at the beginning of its legal opening. It has entered a new phase. The key question now is how a fast-growing private market can combine patient access, medical quality, and long-term trust. Germany can play an important role here as a partner, reference market, and supply chain hub. This applies not only to products, but also to expertise in pharmaceutical quality, pharmacy-based care, import processes, documentation, and everyday medical practice.

The relevance of these questions was also clear at Cannabis Europa, which took place in London on 26 and 27 May 2026. The UK medical cannabis market is growing quickly, but it also faces the challenge of bringing private care, regulatory clarity, and reliable quality standards closer together. For Germany, this creates a clear European opportunity: the experience built here can help other markets integrate medical cannabis into care in a more professional, reliable, and patient-centred way.

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@www.cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

Best wishes from both of us,